StockData

Assembly Biosciences vs Bicycle Therapeutics

ASMB and BCYC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASMB and BCYC compare

Assembly Biosciences is the larger company, worth 1.9 times as much as Bicycle Therapeutics ($433M against $223M).

Bicycle Therapeutics grew revenue faster over the last twelve months (195% versus 125% for Assembly Biosciences).

Assembly Biosciences keeps more of each dollar of sales as profit, with a net margin of −0.06% compared with −170% at Bicycle Therapeutics.

Assembly Biosciences scores higher on the StockData Score (12 against 11 for Bicycle Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASMBBCYC
Size and price
Market cap$433M$223M
Share price$21.29$3.18
Change, 1 year−40.1%−51.8%
Change, 5 years−24.5%−94.2%
Beta (5Y)1.012.11
Employees73288
StockData Score
Total score12 (better)11
Valuation score23 (better)
Growth score12 (better)
Performance score3 (better)2
Health score6 (better)4
Dividend score00
Valuation
P/S5.8×2.7× (better)
P/B1.4×0.4× (better)
FCF yield−8.9% (better)−79.4%
Fair value$24.73$16.02
Margin of safety13.9%80.2% (better)
Growth
Revenue growth (TTM)125%195% (better)
Revenue growth, 5Y average−1.8%47.5% (better)
Profitability
Operating margin−11.8% (better)−189%
Net margin−0.06% (better)−170%
FCF margin−51.5% (better)−212%
Return on equity−0.03% (better)−25.2%
Return on invested capital–−4543%
Financial health
Debt / equity0.000.00
Interest coverage–−815.6×
Current ratio13.99 (better)12.09
Altman Z-score8.00 (better)−0.09
Piotroski F-score4 (better)2
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions92.1%53.4%
Held by insiders29.3%21.3%
Insider net buying, 12 months−$252K (better)−$523K
Short interest, % of float21.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.